Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Goodwill & Intangibles: 2021-2025

Historic Goodwill & Intangibles for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $113.6 million.

  • Xeris Biopharma Holdings' Goodwill & Intangibles fell 8.71% to $113.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.6 million, marking a year-over-year decrease of 8.71%. This contributed to the annual value of $121.8 million for FY2024, which is 8.18% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Goodwill & Intangibles stood at $113.6 million, which was down 2.33% from $116.4 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Goodwill & Intangibles high stood at $154.3 million for Q4 2021, and its period low was $113.6 million during Q3 2025.
  • Its 3-year average for Goodwill & Intangibles is $127.2 million, with a median of $127.2 million in 2024.
  • Data for Xeris Biopharma Holdings' Goodwill & Intangibles shows a maximum YoY fell of 8.71% (in 2025) over the last 5 years.
  • Over the past 5 years, Xeris Biopharma Holdings' Goodwill & Intangibles (Quarterly) stood at $154.3 million in 2021, then fell by 7.03% to $143.5 million in 2022, then decreased by 7.56% to $132.6 million in 2023, then dropped by 8.18% to $121.8 million in 2024, then decreased by 8.71% to $113.6 million in 2025.
  • Its last three reported values are $113.6 million in Q3 2025, $116.4 million for Q2 2025, and $119.1 million during Q1 2025.